Celularity Inc
NASDAQ:CELU

  • LAST PRICE
    2.4600
  • TODAY'S CHANGE (%)
    0.2100 (9.3333%)
  • Bid / Lots
    2.3300/ 2
  • Ask / Lots
    2.3800/ 3
  • Open / Previous Close
    2.4600 / 2.2500
  • Day Range
    2.1183
    3.7000
  • 52 Week Range
    1.3000
    7.9700
  • Volume
    4,621,522

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CELU
Celularity Inc
49.5M
-0.4x
---
AADI
Aadi Bioscience Inc
53.5M
-0.9x
---
PRE
Prenetics Global Ltd
58.8M
-1.2x
---
HOOK
HOOKIPA Pharma Inc
37.9M
-0.6x
---
CARA
Cara Therapeutics Inc
18.0M
-0.2x
---
ICCC
ImmuCell Corp
32.1M
-6.9x
---
As of 2024-11-15

Company Information

Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).

Contact Information

Headquarters
170 Park AveFLORHAM PARK, NJ, United States 07932
Phone
908-768-2170
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer
Robert Hariri
Chief Financial Officer
David Beers
President - Degenerative Disease
Stephen Brigido
Senior Executive Vice President, Chief Administrative Officer, General Manager
John Haines
Executive Vice President, General Counsel
K. Harold Fletcher

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$49.5M
Revenue (TTM)
$42.7M
Shares Outstanding
22.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.63
EPS
$-5.77
Book Value
$2.11
P/E Ratio
-0.4x
Price/Sales (TTM)
1.2
Price/Cash Flow (TTM)
---
Operating Margin
-308.18%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.